Segment information (Tables)

12 Months Ended

Dec. 31, 2015

Segment Reporting [Abstract]

Revenues

Revenues were as follows (in millions):

	Years ended December 31,
	2015		2014		2013
Product sales:
ENBREL	$	5,364	$	4,688	$	4,551
Neulasta®	4,715		4,596		4,392
Aranesp®	1,951		1,930		1,911
EPOGEN®	1,856		2,031		1,953
Sensipar®/Mimpara®	1,415		1,158		1,089
XGEVA®	1,405		1,221		1,019
Prolia®	1,312		1,030		744
NEUPOGEN®	1,049		1,159		1,398
Vectibix®	549		505		389
Nplate®	525		469		427
Kyprolis®	512		331		73
Other	291		209		246
Total product sales	20,944		19,327		18,192
Other revenues	718		736		484
Total revenues	$	21,662	$	20,063	$	18,676

Geographical information with respect to revenues and long-lived assets

Certain geographic information with respect to revenues and long-lived assets (consisting of property, plant and equipment) was as follows (in millions):

	Years ended December 31,
	2015		2014		2013
Revenues:
United States	$	17,167	$	15,396	$	14,480
Rest of the world (ROW)	4,495		4,667		4,196
Total revenues	$	21,662	$	20,063	$	18,676

	December 31,
	2015		2014
Long-lived assets:
United States	$	2,275	$	2,544
Puerto Rico	1,679		1,771
ROW	953		908
Total long-lived assets	$	4,907	$	5,223

Revenues earned from major customers

Certain information with respect to these customers was as follows (dollar amounts in millions):

	Years ended December 31,
	2015			2014			2013
AmerisourceBergen Corporation:
Gross product sales	$	10,038		$	9,142		$	8,527
% of total gross revenues	34		%	34		%	35		%
% of U.S. gross product sales	42		%	43		%	44		%
McKesson Corporation:
Gross product sales	$	8,766		$	8,011		$	6,440
% of total gross revenues	30		%	30		%	27		%
% of U.S. gross product sales	34		%	35		%	32		%
Cardinal Health, Inc.:
Gross product sales	$	5,045		$	3,407		$	3,209
% of total gross revenues	17		%	13		%	13		%
% of U.S. gross product sales	21		%	16		%	17		%